Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Morse Asset Management Inc

Morse Asset Management Inc cut its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,102 shares of the medical equipment provider’s stock after selling 350 shares during the quarter. Intuitive Surgical makes up 1.8% of Morse Asset Management Inc’s investment portfolio, making the stock its 16th largest position. Morse Asset Management Inc’s holdings in Intuitive Surgical were worth $7,608,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Gilbert & Cook Inc. raised its holdings in Intuitive Surgical by 6.5% in the 4th quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock valued at $1,160,000 after acquiring an additional 211 shares during the last quarter. TrinityPoint Wealth LLC increased its stake in Intuitive Surgical by 21.5% in the fourth quarter. TrinityPoint Wealth LLC now owns 1,081 shares of the medical equipment provider’s stock valued at $365,000 after purchasing an additional 191 shares during the last quarter. Ontario Teachers Pension Plan Board lifted its position in Intuitive Surgical by 3.7% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 3,062 shares of the medical equipment provider’s stock worth $1,033,000 after buying an additional 109 shares during the period. US Bancorp DE boosted its stake in Intuitive Surgical by 12.7% in the 4th quarter. US Bancorp DE now owns 69,919 shares of the medical equipment provider’s stock worth $23,588,000 after buying an additional 7,880 shares during the last quarter. Finally, Commerce Bank boosted its stake in Intuitive Surgical by 3.4% in the 4th quarter. Commerce Bank now owns 18,157 shares of the medical equipment provider’s stock worth $6,125,000 after buying an additional 590 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ISRG. Stifel Nicolaus increased their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Barclays increased their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. Citigroup lifted their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. BTIG Research upped their price objective on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Finally, The Goldman Sachs Group initiated coverage on Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $486.20 on Monday. The firm has a market capitalization of $172.46 billion, a PE ratio of 87.76, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $496.18. The stock’s 50 day moving average price is $468.01 and its 200 day moving average price is $425.38.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.18 earnings per share. On average, analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Mark Brosius sold 2,115 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the transaction, the insider now directly owns 295 shares in the company, valued at $145,113.45. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock valued at $25,528,753 in the last ninety days. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.